^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Triple Negative Breast Cancer
    Drug:carboplatin (Tubulin polymerization promoter)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    10/08/2020
    Excerpt:
    …triple negative recurrent/stage IV breast cancer and germline BRCA1/2 mutations, the NCCN Panel has included platinum agents (cisplatin and carboplatin) as preferred treatment options.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Sci Rep
    Title:

    Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts.

    Published date:
    03/29/2021
    Excerpt:
    We developed patient-derived xenografts (PDXs) from several chemotherapy-naïve TNBC samples to assess the antitumor activity of single drugs and combinations of drugs....In BRCA1/PALB2 mutated tumors, carboplatin was the most active drug in reducing tumor volume.
    DOI:
    10.1038/s41598-021-85962-4
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

    Published date:
    06/10/2015
    Excerpt:
    Patients (N = 86; 69 as first-line therapy) received cisplatin (n = 43) or carboplatin (n = 43). RR was 25.6% (95% CI, 16.8% to 36%) and was numerically higher with cisplatin (32.6%) than with carboplatin (18.7%). RR was 54.5% in patients with germline BRCA1/2 mutations (n = 11)...Platinum agents are active in mTNBC, especially in patients with germline BRCA1/2 mutations.
    DOI:
    10.1200/JCO.2014.57.6660
    Trial ID:
    NCT00483223
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Sci Transl Med
    Title:

    Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas

    Published date:
    07/06/2022
    Excerpt:
    To this end, we analyzed a cohort of 43 TNBC PDXs with known response to both single-agent platinum (either carboplatin, n = 36, or cisplatin, n = 7) and single-agent docetaxel….By contrast, 90.9% of BRCAmut PDXs (10 of 11; P = 0.005) had a response, including seven of eight BRCA1mut and three of three BRCA2mut models (Fig. 2C and table S3).
    DOI:
    10.1126/scitranslmed.abn1926